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Efficacy of Acceptance and Commitment
Therapy in Daily Life (ACT-DL) in early
psychosis: study protocol for a multi-centre
randomized controlled trial
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Abstract
Background: Psychotic experiences, social functioning and general psychopathology are important targets for early
intervention in individuals with Ultra-High-Risk state (UHR) and a first-episode psychosis (FEP). Acceptance and
Commitment Therapy (ACT) is a promising, next-generation Cognitive Behavioural Therapy (CBT) that aims to
modify these targets, but evidence on sustainable change and its underlying mechanisms in individuals’ daily lives
remains limited. The aim of the INTERACT study is to investigate the efficacy of a novel ecological momentary
intervention, Acceptance and Commitment Therapy in Daily Life (ACT-DL) in a multi-centre randomised controlled
trial of individuals with UHR or FEP.
Methods/design: In a multi-centre randomised controlled trial, individuals aged 16–65 years with UHR or FEP will be
randomly allocated to ACT-DL in addition to treatment as usual (TAU) as the experimental condition or a control
condition of TAU only, which will include – for the entire study period – access to routine mental health care and, where
applicable, CBT for psychosis (CBTp). Outcomes will be assessed at baseline (i.e. before randomisation), post-intervention
(i.e. after the 8-week intervention period), and 6-month and 12-month follow-ups (i.e. 6 and 12months after completing
the intervention period) by blinded assessors. The primary outcome will be distress associated with psychotic experiences,
while secondary outcomes will include (momentary) psychotic experiences, social functioning and psychopathology.
Process measures to assess putative mechanisms of change will include psychological flexibility, stress sensitivity and
reward experiences. In addition, acceptability, treatment adherence and treatment fidelity of ACT-DL will be assessed.
Discussion: The current study is the first to test the efficacy of ACT-DL in individuals with UHR and FEP. If this trial
demonstrates the efficacy of ACT-DL, it has the potential to significantly advance the treatment of people with UHR and
FEP and, more generally, provides initial support for implementing mHealth interventions in mental health services.
Trial registration: Netherlands Trial Register, ID: NTR4252. Registered on 26 September 2013.
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Background
The state of Ultra-High-Risk (UHR) (also known as an At-
Risk Mental State (ARMS) or High-Risk (HR) state) [1, 2] is
associated with an increased risk of developing a first-
episode psychosis (FEP), with meta-analytic evidence sug-
gesting that conversion to FEP is most likely to occur
within 2 years (risk estimate, 29%; 95% CI, 23–36) and to
plateau from the third year after presentation to mental
health services (risk estimate, 36% after 3 years, approxi-
mately 35% after 10 years) [3, 4]. This has been taken to
suggest that the UHR state is temporally and phenomeno-
logically continuous with FEP [5], together reflecting the
early stages of psychotic disorder [1, 2, 5–7]. Further, social
functioning of UHR individuals, who do neither convert to
psychosis nor remit, has been reported to be lower than in
healthy controls and remarkably similar to those who con-
vert to psychosis [8]. It has been argued that providing an
avenue for help in individuals with UHR is important to re-
duce distress associated with psychotic experiences and im-
paired functioning to prevent deterioration and persistence
prior to the onset of full-blown psychotic symptoms [9].
While sustained periods of remission occur after the first
onset of a psychotic disorder [10], persisting psychotic
symptoms are associated with significant levels of distress
[11, 12] and poor long-term functioning and social out-
comes have been reported for the majority of FEP individ-
uals [10, 13], who face a marked mortality gap compared
with the general population [14].
A number of psychological mechanisms have been
proposed by current aetiological models that may con-
tribute across different phenomenological and temporal
stages to the development of psychosis [15–20]. One
mechanism that has been repeatedly suggested to play
an important role is behavioural sensitisation, which has
been posited to amplify the stress response in individuals
with increased genetic and/or socio-environmental risk,
such that they experience a greater response to even
minor stressors and daily hassles, which, in turn, con-
tributes to pushing them along a pathway to psychosis
over time [21]. At the behavioural level, the most com-
monly used marker of this underlying process of behav-
ioural sensitisation is stress sensitivity, characterised by
stronger negative emotional reactions to minor stressors
in daily life [22, 23]. Previous research suggests that
emotional reactivity to minor stressful events, activities,
and social situations is increased in individuals with
UHR [23, 24] and FEP [23]. At the same time, it has
been shown that deficits in reward experience are linked
to motivational impairments in psychosis [25, 26].
Developing and evaluating interventions that directly
modify these putative mechanisms in daily life to reduce
the intensity of psychotic experiences at an early stage is
a promising strategy for preventing transition to, and
improving outcomes of, psychosis [23, 27–29]. Building
on recent advances in the field of mobile Health
(mHealth) interventions [30], we have recently proposed
an ecological interventionist causal model approach for
targeting psychological mechanisms in daily life [29].
This approach draws on ecological momentary interven-
tions (EMIs) (as proposed by our own group [28, 29]
and others [31]), which deliver real-time psychological
interventions in daily life, thereby, enabling individuals
to access interventions that are tailored to what a person
needs in a given moment and context, with the goal of
producing changes in mechanisms that lead to sustain-
able change in intended outcomes under real-world con-
ditions [29].
While the initial evidence suggests that psychological
interventions such as Cognitive Behavioural Therapy
(CBT) may be efficacious in reducing transition rates in
individuals with UHR, there is still only a small number
of methodologically robust studies to investigate this
issue, and evidence on sustainable change in relation to
distress associated with symptoms, social functioning as
well as the above-mentioned psychological mechanisms
remains very limited [32–34]. Recently, there has been
increasing interest in Acceptance and Commitment
Therapy (ACT), which is a next-generation CBT target-
ing the relationship of individuals with their feelings and
thoughts rather than their content, with the overarching
goal of enhancing individuals’ psychological flexibility
[35, 36]. ACT aims to train individuals in core psycho-
logical processes of acceptance (e.g. of unpleasant,
stressful feelings and thoughts), non-judgemental con-
tact with the present moment, values, committed action,
self as context, and cognitive defusion [35, 37–39].
While ACT components targeting acceptance are likely
to be effective in attenuating stress sensitivity, ACT
components targeting commitment (values, committed
action) are likely to enhance reward-related motivated
action. There is good evidence on the feasibility and ac-
ceptability of ACT in people with psychosis [40, 41]. Ini-
tial evidence further suggests that ACT may reduce
hospital re-admission rates, psychotic and affective
symptoms, social impairment, and distress associated
with hallucinations in this population [42–45]. While
some studies have reported an effect of ACT on
hypothesised mechanisms (such as experiential avoid-
ance or belief flexibility about symptoms) [39, 40, 44], a
recent RCT in people with persisting psychotic symp-
toms did not find an effect on targeted mechanisms,
calling for improved investigation of psychological pro-
cesses underlying change in distress and other outcomes
[45]. Further, our understanding of whether, and if so
how, therapeutic effects translate into individuals’ daily
lives remains very limited.
Delivering ACT and evaluating its effects on putative
mechanisms in daily life based on principles of EMIs is,
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therefore, both timely and eminently important. Ac-
ceptance and Commitment Therapy in Daily Life
(ACT-DL) has recently been developed for enhancing
the therapeutic effects of ACT under real-world condi-
tions [28–30, 46]. ACT may be particularly amenable to
be implemented as an EMI, as it emphasises the con-
text in which a behavior occurs as well as the function
of this behavior in a given context [46]. In a recently
completed pilot study to evaluate the acceptability and
clinical feasibility of ACT-DL in a heterogeneous clin-
ical sample of patients with mental disorder, very good
completion rates, use of exercises, and positive user ex-
perience were found [47], but there is no robust, trial-
based evidence on its effects in the early stages of
psychosis.
Against this background, the aim of the current study
is to investigate the efficacy of ACT-DL in a multi-
centre randomised controlled trial of patients with UHR
or FEP (INTERACT). The manualised ACT-DL inter-
vention will be administered to UHR and FEP patients
in addition to treatment as usual (TAU) (experimental
condition) and compared to a control condition of TAU
only, which will be standard mental health care includ-
ing Cognitive Behavioural Therapy for psychosis (CBTp)
where applicable. Specifically, the study aims to:
1. Test the efficacy of ACT-DL on reducing distress
associated with psychotic experiences at post-
intervention, 6-month and 12-month follow-ups
(primary outcome)
2. Test the efficacy of ACT-DL on reducing (moment-
ary) psychotic experiences, psychopathology, and
improving social functioning (secondary outcomes),
as well as on reducing stress sensitivity and enhan-
cing reward experience and psychological flexibility
(process measures to assess mechanisms of change)
at post-intervention, 6-month, and 12-month
follow-ups
3. Examine, consistent with established credibility
criteria [48], the effects of ACT-DL in UHR com-
pared with FEP individuals in a priori planned sub-
group analyses
4. Assess the acceptability, treatment adherence and




In a multi-centre randomised controlled trial, individ-
uals aged 16–65 years with UHR or FEP will be
randomly allocated to ACT-DL in addition to TAU as
the experimental condition or a control condition of
TAU only, which will include routine mental health
care and, where applicable, CBTp. Participants will be
recruited from mental health services in the
Netherlands and Flanders, Belgium. Outcomes will be
assessed at baseline (i.e. before randomisation), post-
intervention (i.e. after the 8-week intervention period),
and 6-month and 12-month follow-ups (i.e. 6 and 12
months after completing the intervention period) by
blinded assessors (see Figs. 1 and 2, and Additional file
1 in Supplementary information). Randomisation will
be conducted by an independent researcher through a
computer-generated sequence. All outcomes will be
assessed and all statistical analyses will be conducted
blind to treatment allocation.
Participants
The study will aim to recruit 150 participants with UHR or
FEP from secondary mental health services at clinical sites
of five centres: (1) Amsterdam (Academic Medical Centre,
Arkin Basis GGZ), (2) The Hague (Parnassia/PsyQ), (3)
Maastricht/Eindhoven (Mondriaan, Virenze, GGZE) (all in
the Netherlands), (4) Flemish-Brabant (Leuven (UPC KU
Leuven), Antwerp (VDIP), Diest (Sint-Annendael), Mortsel
(PCM)), and (5) East/West Flanders (Brugge (OLV), Melle
(Karus), Sint Niklaas (VDIP)) (all in Belgium). Individuals
receiving care from these secondary mental health services
will be approached by a clinician of these services, who will
provide initial information about the study. Individuals,
who are interested to take part in the study, will be asked
for their consent to be approached by a member of the re-
search team to learn more about the study. If the potential
participant agrees, they will be fully informed about the
study in a face-to-face session or on the phone by a re-
searcher and, after 1 week, asked for written informed con-
sent. Full eligibility assessment will be conducted by the
researcher once participants have provided written in-
formed consent, which can be withdrawn at any time with-
out any negative consequences for participants. Participants
will be rewarded financially for complete participation, and
travel expenses will be fully reimbursed.
Inclusion criteria
The inclusion criteria are as follows: (1) aged 16–65
years; (2) an UHR (without prior use of antipsychotic
medication) or FEP (onset within last 3 years) as assessed
by the Comprehensive Assessment of At Risk Mental
State (CAARMS) [1] and Nottingham Onset Schedule
(NOS) [49]; (3) sufficient command of the Dutch lan-
guage to follow instructions for assessment of outcomes
and receiving the intervention; and (4) ability to provide
written informed consent.
Exclusion criteria
The exclusion criteria are as follows: (1) a primary
diagnosis of alcohol/substance abuse and dependence,
assessed with the Mini-International Neuropsychiatric
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Interview (MINI) [50]; and (2) severe endocrine, car-
diovascular or brain disease.
Interventions
Control condition: treatment as usual (TAU)
Participants allocated to the treatment as usual (TAU)
control condition will continue to receive all the treat-
ment they received prior to the start of the study. This
will include good standard care delivered according to
local and national service guidelines and protocols by
their general practitioner, psychiatrist and other mem-
bers of the mental health care team. Standard mental
health care will include CBTp at some sites, which will
be assessed together with other service contacts using a
service-use checklist to monitor variation in the delivery
of mental health services and allow for planned sub-
group analysis.
Experimental condition: ACT-DL + TAU
Participants allocated to the experimental condition will
receive ACT-DL with trained clinicians within an 8-
week period in addition to TAU, which will consist of all
the treatment that they received prior to the start of the
study and include all the input from their general practi-
tioner, psychiatrist, and other members of the mental
health care team that they would receive if they did not
participate in the study, with the exception of manua-
lised CBTp. The intervention can be discontinued by
participants at any time upon request without any nega-
tive consequences.
Fig. 1 Anticipated study flowchart
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The manualised ACT-DL intervention consists of eight
ACT training sessions (including one session for psychoe-
ducation) administered face-to-face by a trained clinician
(i.e. psychologists having received a 5-day training in
ACT-DL and receiving fortnightly supervision sessions for
the purposes of the trial), each for around 45–60min, and
an ACT-based EMI, which participants will receive follow-
ing randomisation to the experimental condition [46],
over an 8-week intervention period. The latter will be ad-
ministered through a smartphone-based app (i.e. the Psy-
Mate™ app) to allow participants to apply the skills that
they have been trained into their daily lives [28–30]. The
first six face-to-face ACT sessions are based on a modified
version of ACT for people with psychosis [35, 43, 44, 51]
and aim to enhance participants’ psychological flexibility
by training them in six core components: creative hope-
lessness, acceptance, cognitive defusion, self as context
and contact with the present moment, values, and com-
mitted action [46, 52]. In the last session, all six compo-
nents will be integrated and reviewed.
The ACT-based EMI will train participants in applying
the ACT techniques and skills from the sessions to their
daily life through exercises and metaphors focussing on
the six ACT components without involvement of the
trained clinician on at least three consecutive days per
week following (from session 2) each face-to-face ses-
sion. On each of these days, participants receive prompts
on the app at eight semi-random moments, asking them
to complete a brief questionnaire on their current mood,
psychotic experiences and activities, with the goal of in-
creasing awareness of their current psychological state.
Participants are then offered either an ACT exercise or
metaphor training them in the ACT component covered
in the face-to-face session. After participants are trained
in each ACT component separately, the EMI is extended
to cover the full range of components in order to train
participants to flexibly adopt ACT skills and techniques
depending on the context. In addition, participants are
asked to apply skills and techniques in situations when
they are most needed (e.g. at times of distress associated
with psychotic experiences, during challenging activities
or situations). After completion of the intervention
period, participants will no longer have access to the
app. Please see Steinhart et al. [46] for a more detailed
account of the ACT-DL intervention.
Outcomes
Following written informed consent and full eligibility
assessment, all eligible patients will be assessed on all
outcomes before randomisation (‘baseline’), after the 8-
week intervention period (‘post-intervention’), and after
a 6-month and 12-month follow-up periods (‘follow-up’)
by blinded assessors (see Fig. 1). Secondary outcomes
and process measures using the Experience Sampling
Fig. 2 Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) Figure
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Method (ESM) will be assessed at baseline, post-
intervention, and 6-month follow-up.
Primary outcomes
The primary outcome of the study is distress associated
with psychotic experiences measured with the mean dis-
tress score of the CAARMS positive symptom subscale
(range 0–100) [1]. The CAARMS is a semi-structured
interview, which is sensitive to change [33] and shows a
high reliability [53].
Secondary outcomes
The secondary outcomes of the study are global and so-
cial functioning, (momentary) psychotic experiences,
and psychopathology. Measures to assesses secondary
outcomes will include the Global Assessment of Func-
tioning (GAF) [54] scale, the Social and Occupational
Functioning Assessment Scale (SOFAS) [55], and the So-
cial Functioning Scale (SFS) [56] to assess global and so-
cial functioning. In addition, the Experience Sampling
Method (ESM), a structured, random time-sampling
diary technique will be used to measure activities and
social contacts ten times per day over a period of six
consecutive days using an established ESM data collec-
tion protocol on a smartphone-based app (the PsyMate™
app) [22–24, 57–60] in order to assess momentary social
functioning [61]. Secondary outcome measures will fur-
ther include the Brief Psychiatric Rating Scale (BPRS)
[62] and the Brief Negative Symptom Scale (BNSS) [63]
to cover the full range of psychotic experiences and psy-
chopathology as well as the CAARMS and Positive and
Negative Syndrome Scale (PANSS) [64] for a-priori
planned subgroup analyses in UHR and FEP partici-
pants. Also, psychopathology will be assessed in daily life
with ESM (including momentary psychotic experiences
and momentary negative affect).
Process measures
Process measures to assess putative mechanisms of
change will include ESM measures of minor stressors,
negative affect, pleasantness of events, and positive affect
to assess stress sensitivity (operationalised as an increase
in negative affect in response to minor stressors) and re-
ward experience (operationalised as an increase in posi-
tive affect in response to pleasant events) at baseline,
post-intervention, and 6-month (and – for non-ESM
measures – 12-month) follow-up [22–24, 57–60]. Psy-
chological flexibility operationalised as the six core ACT
competences (see above) will be measured using the Ac-
ceptance and Action Questionnaire [65, 66], the Five
Facet Mindfulness Questionnaire [67], the Flexibility
Index Test [68], and the ESM. Cognitive flexibility will
be measured using the PSYRATS to assess belief flexibil-
ity [69], the beads task to assess reasoning bias [70], and
experimental Experience Sampling Methodology (eESM)
task for measuring liberal acceptance bias [71]. In
addition, the Temporal Experience of Pleasure Scale
(TEPS) [72] will be used to assess anticipatory and con-
summatory pleasure and, more broadly, reward experi-
ence. The therapeutic alliance will be assessed using the
Working Alliance Inventory [73, 74] and will involve
clinician and patient ratings. In addition, the app-based
EMI of ACT-DL will provide detailed process measures
of mood, psychotic experiences and activities in the ex-
perimental condition.
Acceptability, treatment adherence and treatment fidelity
Acceptability of ACT-DL will be assessed at post-
intervention through a questionnaire asking participants
to evaluate ease of use, accessibility and comprehensive-
ness of various components of the intervention. The
app-based EMI of ACT-DL will further provide detailed
data on treatment adherence to ACT-DL (e.g. number
of exercises completed per week). Treatment fidelity will
be rated based on a random selection of audio tapes of
three training sessions recorded by clinicians delivering
ACT-DL using an ACT-DL adherence checklist covering
all core ACT and EMI components [46].
Other measures
Other measures will assess socio-demographic charac-
teristics, alcohol/substance use (Composite International
Diagnostic Interview [75], MINI [50]), current and past
medication use, and IQ (Dutch Adult Reading Test [76])
as potential confounders that may be associated with
primary and secondary outcomes. Service use will be
assessed using a therapy classification checklist. Also,
personality (Eysenck Personality Questionnaire [77]),
trait anxiety (State-Trait Anxiety Inventory [78]), depres-
sion (Beck Depression Inventory-II [79]), psychotic expe-
riences (Prodromal Questionnaire Long Version [80]),
attachment (Psychosis Attachment Measure [81]), and
childhood trauma (Childhood Trauma Questionnaire
[82]) will be assessed.
Sample size
Previous studies suggest that third-wave CBT [40, 83, 84],
including ACT [40, 44], may yield reductions in psychotic
experiences of moderate to large effect size. Consistent
with previous research [44], the power calculation is based
on the primary outcome of a reduction in distress associ-
ated with psychotic experiences of moderate effect size
(i.e. in line with Gaudiano and Herbert [44]) measured
with the CAARMS. Power simulation in R indicates that a
sample size of n = 150 participants (75 experimental, 75
control condition) will be sufficient to test our primary hy-
pothesis of the effect of condition (ACT-DL + TAU vs.
TAU) on distress associated with psychotic experiences at
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all three time points (i.e. post-intervention, 6-month and
12-month follow-ups), which will be tested using an
omnibus test of no difference between the two conditions
at all three time points against the two-sided alternative
hypothesis that there is a difference at one (or more) of
the three follow-up time points, while controlling for base-
line distress associated with psychotic experiences. Specif-
ically, we expect an attrition rate of 31%, resulting in a loss
to follow-up of 23 individuals per condition on average.
Hence, we will recruit a total sample of n = 150 partici-
pants (75 per arm) at baseline to the study, which allows
for a 31% attrition rate and leaves n = 104 participants to
detect a medium effect size of d = 0.5 at (at least) one of
the post-intervention and follow-up time points, with a
power of 0.92 when testing at alpha = 0.05. Power simula-
tion further indicates that a sample of 150 participants,
will be sufficient to detect a large effect size (Cohen’s d =
0.8) at p < 0.05 for the difference in the effect of condition
on distress associated with psychotic experiences between
FEP and UHR with a power of 0.75 at post-intervention
and follow-up in a-priori planned subgroup analysis, while
allowing, again, for a 31% attrition rate (notably, given the
power calculation expected this attrition rate to be con-
stant at all three time points and not to increase – as is ex-
pected – over time (see Fig. 1), power was under-
estimated for this secondary analysis). Hence, this sample
size will allow us to test the secondary hypothesis whether
there is a clinically meaningful difference (of large effect
size) between FEP and UHR that would be relevant to be
considered in the implementation of ACT-DL in routine
care for these patient groups.
Randomisation and blinding
Participants will be randomised at a 50:50 ratio to the
experimental or control condition at the level of the in-
dividual participant by an independent researcher
through a computer-generated sequence following in-
formed consent, full eligibility assessment, and assess-
ment of all outcome measures. Block randomisation
will be carried out in blocks of six participants, with
stratification for the five centres (Amsterdam, The
Hague, Maastricht/Eindhoven, Flemish-Brabant, East/
West Flanders) and two groups of UHR and FEP
(expecting a 50:50 ratio of UHR and FEP to be included
in the sample). The researchers will be blind to the al-
location of participants to the experimental and control
group of the study. There will be a contact person for
any questions regarding the procedure that is not in-
volved in any testing to allow researchers to be blind
towards the allocation of participants when assessing
outcomes. Any breaks in blindness will be documented
and another researcher will be allocated to complete
the next set of assessments where possible.
Assessment of safety
We will monitor and record any serious adverse events
throughout the entire study period. These are any serious
untoward incidents that result in death, persistent or sig-
nificant disability or incapacity, require (extension of) hos-
pitalisation or are life-threatening. Serious adverse events
are not expected to occur as a result of the intervention.
All serious adverse events will be reported to the accre-
dited Medical Ethics Review Committees (MERC). If there
are concerns about unexpectedly high rates of serious ad-
verse events, this will be investigated further in interim
analyses and if this yields any safety or ethical concerns
the Trial Management Committee will terminate the trial
prematurely.
Statistical analysis
The investigators will access the final trial dataset to test
the primary hypothesis of a reduction in distress associ-
ated with psychotic experiences measured with the
CAARMS using a linear regression model with distress
at all three time points (i.e. post-intervention, 6-month
and 12-month follow-ups) as the dependent variable and
distress at baseline, condition (ACT-DL + TAU vs.
TAU), time (as a three-level factor), centre (as a five-
level factor), the baseline × time interaction, and the
condition × time interaction as independent variables,
according to the intention-to-treat principle. Within-
subject clustering of repeated measures will be taken
into account by allowing residuals within subjects to be
correlated with a completely unstructured variance-
covariance matrix.
The model will be fitted using restricted maximum
likelihood estimation using Stata 15 [85]. This will allow
for the use of all available data under the assumption
that data is missing at random and if all variables associ-
ated with missing values are included in the model [86,
87]. Hence, bias due to attrition over time, due to differ-
ence between groups, or as a function of baseline dis-
tress is already mitigated by the model. Potential bias
due to missing outcomes will be assessed in descriptive
analyses of baseline characteristics stratified by missing
data for the primary outcome and condition as follows:
(a) experimental condition with no missing primary out-
come at post-intervention time point, (b) experimental
condition with missing primary outcome at post-
intervention time point, (c) control condition with no
missing primary outcome at post-intervention time
point, and (d) control condition with missing primary
outcome at post-intervention time point [88, 89].
The main effect of condition will be tested via an
omnibus test of no difference between the two condi-
tions at all three time points (Wald-type test with df = 3
and alpha = .05). Should the omnibus test be statistically
significant, then the three time-specific contrasts will be
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examined to determine at which time points significant
differences are present (each tested at alpha = .05). Sec-
ondary hypotheses and analyses of process measures to
assess putative mechanisms of change will be tested fol-
lowing the same steps. Given that block randomisation
will be carried out in blocks of six participants, with
stratification for centre and group, all analyses will in-
clude centre and group as covariate, even though there
is little reason to expect noteworthy clustering of out-
comes by centre.
In addition, multilevel mediation analysis will be used
to test indirect effects of condition on primary outcomes
(distress associated with psychotic experiences) and sec-
ondary outcomes (psychotic experiences, psychopath-
ology, social functioning) via pathways through putative
mechanisms of change (psychological flexibility, stress
sensitivity, reward experience). Multilevel mediation
models will be fitted in MPlus, Version 7 [90], to control
for within-subject clustering of multiple time points [91,
92], using the MLR estimator, which allows for the use
of all available data under the assumption that data is
missing at random (if all variables associated with miss-
ing values are included in the model). In a two-level
model, multiple time points (level 1) will be treated as
nested within subjects (level 2). The total effect of condi-
tion (level 2) on primary/secondary outcomes (level 1)
will be apportioned into direct and indirect (or, syn-
onymously, mediating) effects through putative mecha-
nisms of change (level 1) using the product of
coefficients strategy. This strategy quantifies the point
estimate of the indirect effect as the product of the coef-
ficient of independent variable on mediator variable
(path a) and the coefficient of mediator variable on
dependent variable (path b). We will use statistical soft-
ware by Selig and Preacher [93] for computing Monte
Carlo confidence intervals and assessing the statistical
significance of indirect effects, given their advantages
over rival methods in the context of multilevel mediation
models [93, 94].
For analysis involving ESM variables, multiple ESM
observations (level 1) will be treated as nested within
time points (baseline, post-intervention, 6-month
follow-ups) (level 2) and time points as nested within
subjects (level 3). Consistent with established credibil-
ity criteria [48], we will further test the effects of
ACT-DL in UHR compared with FEP individuals in
a-priori planned subgroup analyses. For subgroup
analyses comparing UHR and FEP, data on the group
variable (UHR, FEP) will be measured prior to ran-
domisation (to address the criterion that the subgroup
characteristic is measured at baseline) to investigate
whether there is a difference in the reduction in dis-
tress associated with psychotic experiences measured
with the CAARMS of large effect size between UHR
and FEP participants (to address the criterion that the
expected difference/effect size is specified a priori)
given that only a large effect size would be relevant
for implementation of ACT-DL in routine care. It will
further be examined whether this effect is (a) consist-
ent across (primary and secondary) outcomes and (b)
supported by indirect evidence on putative mecha-
nisms of change (psychological flexibility, stress
sensitivity, reward experience). In more exploratory
sensitivity analyses, we will compare ACT-DL + TAU,
CBTp + TAU and TAU only to investigate whether
the reduction in distress associated with psychotic ex-
periences measured with the CAARMS will be greater
for CBTp + TAU than TAU only as well as for ACT-
DL than CBTp.
Research governance
Maastricht University is the study sponsor. The trial has
received a favourable ethical opinion from the MERC at
Maastricht University Medical Centre (MUMC), the
Netherlands (reference: NL46439.068.13) and the Univer-
sity Clinic Leuven, Belgium (reference: B322201629214).
Any amendments to the study protocol will be submitted
to the MERC for approval and then communicated to the
sponsor, funder, and centres. The protocol will also be up-
dated in the clinical trial registry. Any deviations from the
study protocol will be fully documented using a breach re-
port form. The principal investigator (PI) will have overall
responsibility for the trial and will be supported by a dedi-
cated research coordinator in the day-to-day management
of the trial. The PI will lead the trial coordinating centre
and, together with the research coordinator, liaise closely
with the site coordinators on recruitment and consent
procedures. The Trial Management Committee will meet
on a monthly basis and consist of all investigators, the re-
search coordinator and site coordinators. It will be chaired
by the PI and manage the day-to-day running of the study,
audit the trial conduct, and oversee preparation of reports
to the MERC. The PI will permit audits, monitoring and
MERC review. Data monitoring and auditing of RCTs ap-
proved by MERC at MUMC is conducted by the Clinical
Trial Center Maastricht, which is independent from the
study sponsor (i.e. Maastricht University). The handling of
the data complies with the Dutch and Belgian Personal
Data Protection Act. If a participant decides to withdraw
their consent, all data from that participant will be
destroyed. This trial does not involve collecting biological
specimens for storage. Data will be handled confidentially
and coded using a number indicating the order of entry.
All materials will be securely stored in line with the Euro-
pean General Data Protection Regulation (GDPR), with
personnel data stored separately from the number-coded
data. We will closely liaise with service user researchers
on dissemination activities throughout the trial.
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Discussion
Psychotic experiences (in particular, distress associated
with these), social functioning, and psychopathology are
important targets for early intervention in individuals
with UHR and FEP [9–13]. ACT is a promising, next-
generation CBT for reducing distress associated with
psychotic experiences, social functioning and psycho-
pathology, but evidence on sustainable change in indi-
viduals’ daily lives, and investigations of the putative
mechanisms underlying such change in distress and
other outcomes, remains limited [32, 33]. Acceptance
and Commitment Therapy in Daily Life (ACT-DL) has
recently been developed for enhancing the therapeutic
effects of ACT and achieving sustainable change in indi-
viduals’ daily life [28–30, 46]. The current study is the
first to test the efficacy of ACT-DL in a multi-centre
randomised controlled trial of patients with UHR or FEP
and includes a detailed investigation of process measures
of putative mechanisms of change, acceptability, treat-
ment adherence and treatment fidelity. If this trial dem-
onstrates the efficacy of ACT-DL, this has the potential
to significantly advance the treatment of people with
UHR and FEP and, more generally, provides initial sup-
port for implementing mHealth interventions in early
intervention services. Findings on putative mechanisms
of change will, at the same time, allow us to assess im-
portant criteria for establishing causality under real-
world conditions [29]. Potential implementation of
ACT-DL in early intervention services will be informed
by detailed data on its acceptability, treatment adherence
and treatment fidelity.
Trial status
This trial is ongoing. The trial started recruitment in
November 2016 and recruitment and outcome assess-
ment will continue until June 2020. The results will be
published in peer-reviewed journals in 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3912-4.
Additional file 1. Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist.
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